Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,222 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,222 shares of the stock in a transaction dated Friday, April 19th. The stock was sold at an average price of $9.34, for a total transaction of $207,553.48. The sale was disclosed in a filing with the SEC, which is available through this link.

Adrian Haigh also recently made the following trade(s):

• On Monday, April 22nd, Adrian Haigh sold 22,223 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $9.32, for a total transaction of $207,118.36.
• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.91, for a total transaction of $220,220.02.
• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.30, for a total value of $228,886.60.

Fennec Pharmaceuticals Price Performance

Shares of FENC stock opened at $9.38 on Tuesday. The stock has a 50-day moving average of $10.05 and a 200-day moving average of $9.40. The stock has a market cap of $254.20 million, a PE ratio of -15.38 and a beta of 0.38. Fennec Pharmaceuticals Inc has a one year low of $6.30 and a one year high of $11.92.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The firm had revenue of $9.74 million for the quarter, compared to analyst estimates of $9.47 million. As a group, research analysts anticipate that Fennec Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Wedbush restated an “outperform” rating and set a $16.00 target price on shares of Fennec Pharmaceuticals in a research report on Monday, March 18th. Craig Hallum lifted their price objective on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Finally, HC Wainwright upped their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Thursday, April 4th.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. AIGH Capital Management LLC increased its holdings in Fennec Pharmaceuticals by 6.9% during the third quarter. AIGH Capital Management LLC now owns 373,526 shares of the company’s stock worth $2,805,000 after buying an additional 24,069 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Fennec Pharmaceuticals during the 3rd quarter worth about $50,000. Gendell Jeffrey L raised its holdings in shares of Fennec Pharmaceuticals by 0.9% in the 3rd quarter. Gendell Jeffrey L now owns 285,992 shares of the company’s stock valued at $2,148,000 after purchasing an additional 2,579 shares during the period. Jump Financial LLC acquired a new stake in Fennec Pharmaceuticals in the 4th quarter valued at about $158,000. Finally, Worth Venture Partners LLC grew its holdings in Fennec Pharmaceuticals by 52.7% during the fourth quarter. Worth Venture Partners LLC now owns 141,500 shares of the company’s stock worth $1,588,000 after purchasing an additional 48,864 shares during the period. Institutional investors own 55.51% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.